Dongkuk Pharmaceutical reported increases in both revenue and operating profit through the third quarter of this year, driven by growth in its health and beauty business and prescription drugs.
The company announced on November 16 that its consolidated revenue for the third quarter reached 768.6 billion won, a 12.4% increase compared to the same period last year. Operating profit for the same period rose by 6.9% to 77.2 billion won. On a standalone basis, revenue was 658.6 billion won, with operating profit at 70.9 billion won, reflecting increases of 17.2% and 23.3%, respectively.
The difference in growth rates between consolidated and standalone results is attributed to its subsidiary, Dongkuk Life Science. The ME business segment faced challenges due to a deteriorating market environment for diagnostic equipment, and revenue and profit declined during the relocation of its contrast agent production facility for global exports. The company expects profitability to improve once the restructuring of its business operations is completed.
The growth was primarily led by the health and beauty division. In North America, the company expanded its distribution network through partnerships with Costco, Ulta Beauty, and Nordstrom. During Amazon Prime Day, its PDRN product ranked first in the eye cream category. In Japan, Dongkuk's products are now available in over 7,500 stores, including Don Quijote and Matsumoto Kiyoshi, and the company has begun targeting Europe, starting with the UK H&B store Boots in the third quarter. Its flagship product, Madeca Cream, surpassed cumulative sales of 100 million units by September.
Sales in the health supplement business increased by over 30% compared to the previous year. The health supplement brand MyFit achieved cumulative sales of 49 billion won since its launch. The company operates 41 stores in major department stores nationwide, and sales at Daiso, where it entered last April, increased by over 330% year-on-year. In February, it launched Dongkuk Health, targeting the low-cost health supplement market with a lineup of nine products, including probiotics and omega-3.
The prescription drug (ETC) division reported a cumulative revenue increase of 8.4% in the third quarter compared to last year. The prostate enlargement treatment Uresko, approved in December, captured over 70% market share within 10 months of its launch. The osteoarthritis treatment Celebron and the ulcer medication Rabeidon also recorded double-digit growth rates. The global business division exceeded its performance targets for the third quarter. It has signed a licensing and supply agreement for Uresko with Spanish pharmaceutical company FAES FARMA to pursue approvals and launches in various countries.
Dongkuk Pharmaceutical plans to commercialize its prostate cancer treatment Lorelin sequentially using its proprietary drug delivery system (DDS) technology, and it aims to accelerate the development of new products, including obesity treatments, acromegaly treatments, and immunosuppressants.
The company announced on November 16 that its consolidated revenue for the third quarter reached 768.6 billion won, a 12.4% increase compared to the same period last year. Operating profit for the same period rose by 6.9% to 77.2 billion won. On a standalone basis, revenue was 658.6 billion won, with operating profit at 70.9 billion won, reflecting increases of 17.2% and 23.3%, respectively.
The difference in growth rates between consolidated and standalone results is attributed to its subsidiary, Dongkuk Life Science. The ME business segment faced challenges due to a deteriorating market environment for diagnostic equipment, and revenue and profit declined during the relocation of its contrast agent production facility for global exports. The company expects profitability to improve once the restructuring of its business operations is completed.
The growth was primarily led by the health and beauty division. In North America, the company expanded its distribution network through partnerships with Costco, Ulta Beauty, and Nordstrom. During Amazon Prime Day, its PDRN product ranked first in the eye cream category. In Japan, Dongkuk's products are now available in over 7,500 stores, including Don Quijote and Matsumoto Kiyoshi, and the company has begun targeting Europe, starting with the UK H&B store Boots in the third quarter. Its flagship product, Madeca Cream, surpassed cumulative sales of 100 million units by September.
Sales in the health supplement business increased by over 30% compared to the previous year. The health supplement brand MyFit achieved cumulative sales of 49 billion won since its launch. The company operates 41 stores in major department stores nationwide, and sales at Daiso, where it entered last April, increased by over 330% year-on-year. In February, it launched Dongkuk Health, targeting the low-cost health supplement market with a lineup of nine products, including probiotics and omega-3.
The prescription drug (ETC) division reported a cumulative revenue increase of 8.4% in the third quarter compared to last year. The prostate enlargement treatment Uresko, approved in December, captured over 70% market share within 10 months of its launch. The osteoarthritis treatment Celebron and the ulcer medication Rabeidon also recorded double-digit growth rates. The global business division exceeded its performance targets for the third quarter. It has signed a licensing and supply agreement for Uresko with Spanish pharmaceutical company FAES FARMA to pursue approvals and launches in various countries.
Dongkuk Pharmaceutical plans to commercialize its prostate cancer treatment Lorelin sequentially using its proprietary drug delivery system (DDS) technology, and it aims to accelerate the development of new products, including obesity treatments, acromegaly treatments, and immunosuppressants.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.